274 related articles for article (PubMed ID: 29415258)
1. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
Ishigooka J; Iwashita S; Tadori Y
Psychiatry Clin Neurosci; 2018 Jun; 72(6):445-453. PubMed ID: 29582518
[TBL] [Abstract][Full Text] [Related]
3. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
[TBL] [Abstract][Full Text] [Related]
4. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
[TBL] [Abstract][Full Text] [Related]
5. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
Citrome L; Ouyang J; Shi L; Meehan SR; Baker RA; Weiss C
J Clin Psychopharmacol; 2019; 39(6):597-603. PubMed ID: 31652166
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms:
Meade N; Shi L; Meehan SR; Weiss C; Ismail Z
J Psychopharmacol; 2020 Aug; 34(8):829-838. PubMed ID: 32648810
[TBL] [Abstract][Full Text] [Related]
7. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
McEvoy J; Citrome L
Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
Ishigooka J; Iwashita S; Tadori Y
Psychiatry Clin Neurosci; 2018 Sep; 72(9):692-700. PubMed ID: 29774628
[TBL] [Abstract][Full Text] [Related]
9. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
[TBL] [Abstract][Full Text] [Related]
13. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.
Correll CU; Shi L; Weiss C; Hobart M; Eramo A; Duffy RA; Weiller E; Baker RA
CNS Spectr; 2019 Oct; 24(5):507-517. PubMed ID: 30306884
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole: A Review in Schizophrenia.
Garnock-Jones KP
CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
17. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
[TBL] [Abstract][Full Text] [Related]
18. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
